Somewhat Critical Media Coverage Somewhat Unlikely to Affect Sonoma Pharmaceuticals (SNOA) Stock Price
Media coverage about Sonoma Pharmaceuticals (NASDAQ:SNOA) has been trending somewhat negative this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a news sentiment score of -0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2190378956912 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Sonoma Pharmaceuticals (SNOA) PT Set at $11.00 by Maxim Group (americanbankingnews.com)
- Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year … – GlobeNewswire (press release) (globenewswire.com)
- Sonoma Pharmaceuticals’ (SNOA) CEO James Schutz on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% (finance.yahoo.com)
A number of research firms have issued reports on SNOA. Zacks Investment Research upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Wednesday, January 10th. Maxim Group lifted their target price on shares of Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Finally, Benchmark began coverage on shares of Sonoma Pharmaceuticals in a research note on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 target price for the company.
TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/13/somewhat-critical-media-coverage-somewhat-unlikely-to-affect-sonoma-pharmaceuticals-snoa-stock-price.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.